General Information
Bortezomib is the first drug of its type – a proteasome inhibitor. It is used for the treatment of multiple myeloma (MM), a blood cancer, and mantle cell lymphoma (MCL), a rare type of non-Hodgkin’s lymphoma. In MM, its use includes retreatment for patients who had previously responded to treatment with bortezomib and relapsed at least six months after completing prior bortezomib treatment.
About the API
Systematic name
[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid
Trade name(s)
Velcade,Neomib, Bortecad
Technology
Synthetic
Molecular Formula
C19H25BN4O4
Molecular Weight
384.24 g/mol
Physical properties
White to off- white powder
Therapeutic category
Oncology
Available formulations
Injectables
Regulations
Brazil DMF
Canada DMF
EU DMF
Japan DMF
Korea DMF
US DMF
Brazil DMF
Canada DMF
EU DMF
Japan DMF
Korea DMF
US DMF